Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open-Label, Randomization Multi-Center Study to Evaluate Efficacy And Safety of FURMONERTINIB MESILATE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBOURING EGFR EXON 20 INSERTION MUTATION

Next Previous
X
Search
Trial Profile

A Phase Ib Open-Label, Randomization Multi-Center Study to Evaluate Efficacy And Safety of FURMONERTINIB MESILATE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBOURING EGFR EXON 20 INSERTION MUTATION

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firmonertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms FAVOUR1
  • Sponsors Allist Pharmaceuticals

    • Most Recent Events

    • 17 Oct 2021 Status changed from suspended to withdrawn prior to enrolment.(The protocol need to review).
    • 29 Jul 2021 Protocol has been amended due to changes in study phase and planned patient number.
    • 29 Jul 2021 Planned number of patients changed from 100 to 20.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top